Prime Highlights
- AITRICS raised ₩35 billion ($23.7 million)in Series C funding, reflecting strong investor confidence.
- The company will use the funds to enhance AI products and accelerate global expansion in Asia and North America.
Key Facts
- Existing and new investors, including Premier Partnersand KB Securities–Solidus Investment, participated in the round.
- Since inception, AITRICS has raised a total of ₩73.1 billion, supporting products like AITRICS-VCand Doc Pro.
Background
Medical AI company AITRICS has raised ₩35 billion ($23.7 million) in its Series C investment round, the company announced on Monday. The round saw participation from nine Korean and foreign venture capital firms and financial institutions.
Existing investors such as Premier Partners, Han River Partners, Mirae Asset Venture Investment, and Shinhan Investment-BSK Investment returned for this round, while KB Securities–Solidus Investment, SV Investment, and Mirae Asset Capital joined as new backers.
AITRICS said the successful fundraising highlights the strength of its technology, the clinical value of its solutions, and the company’s potential to scale globally. The company will use the new capital to improve key products, including AITRICS-VC (Vital Care), which predicts early patient deterioration, and V.Doc Pro, an AI co-pilot that supports medical teams with real-time insights. Part of the funding will also go toward research and development for new medical AI pipelines.
The company plans to accelerate global operations, starting with Asia. It set up a Japanese subsidiary in March and aims to expand into Vietnam and Hong Kong. AITRICS set up a U.S. subsidiary in late 2023 to prepare for entry into North America. Its recent partnership with the Mayo Clinic Platform has also strengthened its model development and plans for global expansion.
AITRICS CEO Kim Kwang-joon said the new investment confirms the company’s direction and long-term growth potential. He added that continued support from investors reinforces trust in the firm’s strategy and products.
SV Investment said it decided to invest after reviewing AITRICS’s strong clinical results, innovative AI solutions, and clear market strategy. The company expects the funding to boost new indications and global expansion.
With the latest round, AITRICS has raised a total of ₩73.1 billion in investments since it was founded, adding to the funds it collected in earlier rounds from 2017 to 2024.
